Ankur R Parikh
Overview
Explore the profile of Ankur R Parikh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
460
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Citrin D, Tan B, Patel N, Doctor V, Ali S, Parikh A, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-7.
PMID: 35135147
No abstract available.
2.
Vicente A, Patel B, Gutierrez-Rodrigues F, Groarke E, Giudice V, Lotter J, et al.
Haematologica
. 2020 Dec;
105(12):2785-2794.
PMID: 33256377
Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by cytopenia and a propensity to develop acute myeloid leukemia (AML). The management of lower-risk (LR) MDS with persistent...
3.
Parikh A
Acta Med Acad
. 2019 Jul;
48(1):78-83.
PMID: 31264435
The landscape of lung cancer treatment is rapidly evolving with the use of genomic testing which helps identify specific mutations or resistance mutations for these heterogenous tumors. Advanced lung cancer...
4.
Lai C, Ranpura V, Wu C, Olnes M, Parikh A, Shenoy A, et al.
Blood Adv
. 2019 Apr;
3(7):980-983.
PMID: 30936058
No abstract available.
5.
Parikh A, Ali S, Schrock A, Albacker L, Miller V, Stephens P, et al.
Lung Cancer (Auckl)
. 2018 May;
9:45-47.
PMID: 29844707
In non-small-cell lung cancer (NSCLC) refractory to standard therapy and which lacks well-known oncogenic drivers, genomic profiling can still identify genomic alterations that may suggest potential sensitivity to targeted therapy....
6.
Niu J, Andres G, Kramer K, Kundranda M, Alvarez R, Klimant E, et al.
Onco Targets Ther
. 2015 Dec;
8:3323-8.
PMID: 26648736
Background: ESR1 mutation has recently emerged as one of the important mechanisms involved in endocrine resistance. The incidence and clinical implication of ESR1 mutation has not been well evaluated in...
7.
Desmond R, Townsley D, Dumitriu B, Olnes M, Scheinberg P, Bevans M, et al.
Blood
. 2013 Dec;
123(12):1818-25.
PMID: 24345753
About a quarter of patients with severe aplastic anemia remain pancytopenic despite immunosuppressive therapy. We have previously demonstrated that eltrombopag has efficacy in this setting with 44% (11/25) of patients...
8.
Parikh A, Olnes M, Barrett A
Semin Hematol
. 2012 Oct;
49(4):304-11.
PMID: 23079060
It is now well accepted that a subgroup of patients with myelodysplastic syndromes (MDS) can recover from pancytopenia following immunosuppressive treatment (IST). For many years immunosuppression with antilymphocyte antibodies has...
9.
Olnes M, Scheinberg P, Calvo K, Desmond R, Tang Y, Dumitriu B, et al.
N Engl J Med
. 2012 Jul;
367(1):11-9.
PMID: 22762314
Background: Severe aplastic anemia, which is characterized by immune-mediated bone marrow hypoplasia and pancytopenia, can be treated effectively with immunosuppressive therapy or allogeneic transplantation. One third of patients have disease...